GlassScriptPhysician profile
Gregory K Wong
NPI 1386977288
$2,130.11
in general payments reported to CMS, 2019-2025
30 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $29.77 · 2021: $390 · 2022: $101 · 2023: $371 · 2024: $577 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,403.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $244.79 | 2020-2023 | |
| Baxter Healthcare | $242.79 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Alcresta Therapeutics, INC. | $212.49 | 2023-2025 | Relizorb |
| Vertex Pharmaceuticals Incorporated | $177.88 | 2019-2025 | Trikafta |
| Advanced Respiratory, INC | $124.69 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.47 | 2021-2025 | Gattex, Eohilia |
| Qol Medical, LLC | $111.39 | 2021-2025 | Sucraid, Sucraid |
| Mirum Pharmaceuticals, INC. | $90.10 | 2023-2025 | Livmarli |
| Digestive Care, INC. | $75.65 | 2023-2025 | Pertzye |
| Genzyme Corporation | $67.81 | 2024-2025 | |
| Chiesi USA, INC. | $61.19 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $61.11 | 2024-2025 | Zenpep |
| Fresenius Kabi USA, LLC | $55.74 | 2023 | Idacio |
| Travere Therapeutics, INC. | $55.51 | 2019-2022 | |
| Rhythm Pharmaceuticals, INC. | $48.22 | 2025 | Imcivree |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $44.51 | 2021 | |
| Abbvie INC. | $40.72 | 2019-2023 | Linzess |
| Sandoz INC. | $39.37 | 2024 | Hyrimoz |
| Mylan Specialty L.P. | $33.25 | 2019-2021 | |
| Dentsply Ih Ab | $33.02 | 2025 | Navina Rectal Catheter Set Regular |
| Neurocrine Biosciences, INC. | $24.42 | 2025 | |
| Albireo Pharma, INC. | $23.80 | 2024 | Bylvay |
| Celltrion USA INC. | $22.74 | 2024 | Zymfentra |
| Ironwood Pharmaceuticals, INC | $21.94 | 2023 | Linzess |
| Shire North American Group INC | $21.33 | 2019 | |
| Olympus America INC. | $20.26 | 2024 | Endoclot Phs |
| Genentech USA, INC. | $19.04 | 2021 | |
| Philips North America LLC | $14.96 | 2020 | |
| Concordia Pharmaceuticals INC. | $13.23 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.